Today, the incidence of cancer in the world is rising, and it is expected that in the next several decades, the number of people suffering from cancer or (the cancer rate) will double. Cancer is defined as the excessive and uncontrolled growth of cells; of course (in simple terms), cancer is considered to be a set of other diseases that ultimately causes normal cells to be transformed into neoplastic cells. One of the most important causes of the onset and exacerbation of cancer is excessive oxidative stress. One of the most important proteins in the inner membrane of mitochondria is Reactive Oxygen Species (ROS) Modulator 1 (ROMO1) that interferes with the production of ROS, and with increasing the rate of this protein, oxidative stress will increase, which ultimately leads to some diseases, especially cancer. In this overview, we use some global databases to provide information about ROMO1 cellular signaling pathways, their related proteins and molecules, and some of the diseases associated with the mitochondrial protein, especially cancer.

No abstract

There is no denying that the massive spread of COVID-19 around the world has worried everyone. The virus can cause mild to severe symptoms in various organs, especially the lungs. The virus affects oxidative stress in the cells. Reactive Oxygen Species modulator 1 (ROMO1) is one of the most important mitochondrial proteins that plays a critical regulatory role in the production of Reactive Oxygen Species (ROS). According to the studies, COVID-19 can promote oxidative stress through some important pathways, for instance, TNF-α and NF-κB routes. Furthermore, ROMO1 is closely related to these pathways and its dysfunction may affect these routes, then promote oxidative stress, and ultimately cause tissue damage, especially in the lungs. Another factor to consider is that the TNF-α and NF-κB pathways are associated with ROMO1, COVID-19, and oxidative stress. To summarize, it is hypothesized that COVID-19 may increase oxidative stress by affecting ROMO1. Understanding the exact molecular mechanisms of ROMO1 in the pathogenesis of COVID-19 can pave the way to find better therapeutic strategies.

Context: Many studies have reported contradictory results about the relationship between selenium levels and the risk of lung cancer. Objectives: This study was performed with the aim of evaluating the relationship between selenium and lung cancer. Methods: The present systematic review and meta-analysis was carried out according to PRISMA guidelines. Using MeSH keywords, two reviewers independently searched international databases including PubMed, Science Direct, Cochrane, EMBASE, Web of Science, CINAHL, EBSCO, and Google Scholar. The data were combined, using comprehensive Meta-Analysis Software Version 2 based on the random effects model. The tests were considered significant at P < 0.05. Results: In 15 high-quality studies including 13 case-control and 2 cohort studies, 84 199 subjects (2 434 cases and 81 765 controls) were studied. The OR of lung cancer in the highest quintile of selenium exposure compared to the lowest quintile was 0.55 (95% CI: 0.35 -0.86, P < 0.01). The results of the standardized mean difference between serum selenium concentrations in lung cancer and healthy groups was -4.77 µg/L (95% CI: -6.31 to -3.23, P < 0.01). This value for toenails selenium in 3 studies (620 cases and 2 709 controls) was -0.13 µg/g (95% CI: -0.22 to -0.03, P < 0.01). In subgroup analysis, it was determined that gender (P = 0.28), type of studies (P = 0.70), and measurement of selenium samples (P = 0.46) were not influencing factors. Conclusions:The results of the study indicated the preventive role of increased selenium levels in the incidence of lung cancer. Moreover, the selenium could be used as a predictive variable.

Background One of the deadliest cancers in the world is gastric cancer. Long non-coding RNAs play prominent roles in cancer. LINC00961, TPT1-AS1, and SAMMSON have recently been discovered, which significantly contribute in various cancers and can affect the tumor size, grade of tumors and the metastasis condition. The aim of this study was to determine LINC00961, SAMMSON and TPT1-AS1 expression in gastric cancer tissues in comparison with healthy adjacent tissues. Methods The number of cancerous tissues and control groups was calculated to be at 40 (n = 40) and were analyzed by Quantitative real-time polymerase chain reaction. Results We found that overexpression of TPT1-AS1 and SAMMSON, and downexpression of LINC00961 in cancerous tissues in comparison with healthy adjacent tissues. A positive association between TPT1-AS1 and SAMMSON expression and tumor grade was observed. The level of mRNA folding change increased in cancer group compared to control group and *P < 0.05 is considered for mRNA folding change. Conclusion Finally, we found that overexpression of TPT1-AS1 and SAMMSON, and downexpression of LINC00961 were observed significantly in gastric cancer tissues in comparison with adjacent non-cancerous tissues. These lncRNAs were suggested as potential tumor markers for the diagnosis and treatment of gastric cancer.

No abstract

Background The present single-center clinical trial was designed to evaluate the potential benefits of L-carnitine supplementation in patients with COVID-19 disease. Methods and patients The study was conducted on 75 patients with mild-to-moderate COVID-19 hospitalized in Shahid Beheshti Hospital-Hamadan, IRAN. The participants were randomly divided into intervention ( n = 32) and control groups ( n = 43). The control group received their standard hospital treatment only. In addition to standard medications, the intervention group received 3000 mg oral L-carnitine daily in three divided doses for five days. The blood samples were collected and para-clinical parameters were measured at the beginning and end of the treatment. Clinical outcomes were also recorded, and data were analyzed using χ 2 and t -tests. Results Higher means of O2 saturation were observed in the intervention rather than in the control group. Mean erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were significantly lower in the intervention group. Furthermore, mean alkaline phosphatase (ALP) activity and lactate dehydrogenase (LDH) were lower in the intervention group. Also, lower mean serum creatine phosphokinase (CPK) was observed in the intervention group. No significant differences were observed in terms of clinical symptoms; however, six patients (14%) in the control group died due to the complications of COVID-19, while all patients in the intervention group survived. Conclusion Taken together, L-carnitine can be considered as a drug supplement in patients with COVID-19. Supplementary Information The online version contains supplementary material available at 10.1007/s43440-022-00402-y.

No abstract